Coagulation factor X human

Specification

• Cat#: THP-0061
• Product Name: Coagulation factor X human
• Description: The product is a plasma-derived human blood coagulation factor. Coagulation Factor X is a vitamin K-dependent, liver-produced serine protease that serves as the first enzyme in the coagulation cascade to form fibrin. It is a two-chain glycoprotein with the molecular weight of approximately 59 kDa. While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.
• Sequences: Not Available
• Species: Human
• Molecular Weight: 59000.0 Da
• Source: Human Plasma
• Cas No: Not Available
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg of the protein by the LAL method
• Biological Activity: 100IU/ml

Pharmaceutical Information

• Pharmaceutical Application: Coagulation factor X human
• Applications: Indicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, or for perioperative management of bleeding in patients with mild hereditary Factor X deficiency.
• Examples of Clinical Use: Bleeding episodes and mild hereditary Factor X deficiency
• Pharmacodynamics: The product solution increases plasma levels of Factor X and can temporarily correct the coagulation defect in these patients, as reflected by decrease in the activated Partial Thromboplastin Time (aPTT) and prothrombin time (PT).
• Mechanism of action: Factor X is an inactive zymogen that is synthesized in the liver, which can be activated by Factor IXa (via the intrinsic pathway) or by Factor VIIa (via the extrinsic pathway). It is composed of a light chain which contains the Gla (glutamic acid) domain and two epidermal growth factor domains, and a heavy chain that contains the catalytic serine protease domain. The conversion of inactive Factor X into the active form Factor Xa requires the cleavage of a 52-residue peptide from the heavy chain and the release of 52-residue activation peptide that contains the His236, Asp228 and Ser379 catalytic site. This activation step can occur through the extrinsic or intrinsic pathway and is considered to be the first step in the common pathway to fibrin formation.
• Affected organisms: Humans and other mammals